PEPID Pulse
  • Blog
  • Alerts
  • Press
  • pepid.com
Select Page
FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

FDA Grants Approval for First Targeted Anticancer Treatment for Relapsed or Refractory Acute Myeloid Leukemia with IDH1 Mutation

by Anna Tan | Aug 3, 2018 | Nursing, Pharmacy, Primary Care

On July 20, 2018, the U.S. Food and Drug Administration (FDA) approved the first acute myeloid leukemia treatment. It is the first approved targeted cancer therapy for patients with relapsed or refractory acute myeloid leukemia (R/R AML), specifically, those screened...

Recent Posts

  • Men’s Health Month – Closing Gaps in Prevention and Early Detection
  • Beyond the Beach – Occupational Skin Cancer Risks in Outdoor Workers
  • Tackling Antimicrobial Resistance: How to fight back against the rise in tough cases
  • The ‘Forever Chemicals’ Crisis: What Healthcare Providers Need to Know About PFAS
  • Top Challenges Faced by Emergency Medicine Residents and How to Overcome Them

Categories

  • Alerts
  • Emergency Medicine
  • Featured Posts
  • Nursing
  • Pharmacy
  • Press & Media
  • Primary Care
  • Uncategorized
PEPID, LLC. All rights reserved